Grace Halsey

Baxdrostat shows potential to represent the first new class of antihypertensive agents approved since 2017.

The Mass General Brigham clinical intervention and study included 10 000 participants and resulted in significant reductions in SBP/DBP and LDL-C.

Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.

Equifax, Experian, and TransUnion announced 3 major changes to medical debt reporting, expected to remove ~70% of medical collection debt tradelines from consumer credit reports.

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

The novel approach to targeted obesity treatment could improve weight loss outcomes, suggest findings from ObesityWeek® 2022.

Study authors saw a positive dose-response relationship driven by hemorrhagic stroke in young adults who were moderate-to-heavy drinkers in their 20s and 30s.

The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

Semaglutide 2.4 mg (Wegovy) weight loss benefits in adolescents mirror those seen in adults, according to phase 3a trial findings presented at ObesityWeek® 2022.

ObesityWeek® 2022. Primary care clinicians report providing on average just 70% of a wide range of clinical weight management services, according to a new survey.

The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.

Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.

ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.

ObesityWeek® 2022. Low awareness of antiobesity medications and concerns about cost, side effects revealed as barriers to wider uptake in a new study.

Black patients were also at significantly increased risk of stroke, bleeding, and mortality vs White patients 1 year following discharge.

The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.

The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.

In patients with prediabetes and untreated type 2 diabetes, a reduced carbohydrate diet improved HbA1c and other metabolic markers vs a usual diet.

Efficacy of the RZV vaccine against herpes zoster infection remained >80% in a long-term follow-up study representing 10 years since initial immunization.

High-dose dexamethasone is often prescribed for critically ill COVID-19 patients although there is no evidence for its efficacy. A new study looked deeper.

The overall US COVID-19 vaccination picture has both bright spots and dark areas. Get a quick look at details from the most recent KFF Vaccine Monitor survey.

The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.

CHEST. After a moderate COPD event, treatment with TT within 30 days significantly reduced risk for exacerbation over 12 months vs treatment after 30 days.

AAFP Board Chair Ransone points to recent data that show two-thirds of long COVID patients are already treated in primary care settings.

Another choice of booster may help increase follow-up vaccination among the 50% of US adults who have yet to get a first booster dose.